Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Despite the standard of care, patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) progress to dialysis, are hospitalized for heart failure and die prematurely. Overactivation of the mineralocorticoid receptor (MR) causes inflammation and fibrosis that damages the kidney and heart. Finerenone, a nonsteroidal, selective MR antagonist, confers kidney and heart protection in both animal models and Phase II clinical studies; the effects on serum potassium and kidney function are minimal. Comprising the largest CKD outcomes program to date, FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) and FIGARO-DKD (FInerenone in reducinG cArdiovascular moRtality and mOrbidity in Diabetic Kidney Disease) are Phase III trials investigating the efficacy and safety of finerenone on kidney failure and cardiovascular outcomes from early to advanced CKD in T2D. By including echocardiograms and biomarkers, they extend our understanding of pathophysiology; by including quality of life measurements, they provide patient-centered outcomes; and by including understudied yet high-risk cardiorenal subpopulations, they have the potential to widen the scope of therapy in T2D with CKD. Trial registration number: FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![FIGURE 5. Comparison of baseline median UACR (mg/g) and mean eGFR (mL/min/1.73 m2) of patients enrolled in recent trials investigating cardiovascular and/or renal outcomes in patients with CKD in T2D (circle sizes are proportional to the population sizes of the trials.) [12, 14, 43–49].](https://figures.cochat.ai/paper-figures/3885cb17fe794e879beb8fb60f6eadd0/investigating-new-treatment-opportunities-for-patients-with-chronic-kidney-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Even with current therapies available [6–10], patients with T2DM and chronic kidney disease (CKD) still experience a significant cardiovascular and renal morbidity and mortality.”
The cited source says what the claim attributes to it.
In the citing paper
“They investigated the efficacy and safety of finerenone, on top of maximum tolerated renin–angiotensin system inhibition, on kidney and cardiovascular outcomes in patients with mild-to-severe CKD in type 2 diabetes (Supplementary material online, Figure S1).3”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Patients with chronic kidney disease (CKD) and type 2 diabetes have high residual cardiorenal morbidity and mortality, despite current therapies,1–5”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Patient characteristics, medications, and demographics at baseline were balanced between patients randomized to finerenone and placebo (Table 2 and Supplementary material online, Table S1; published previously3).”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · cited 1×
“The available steroidal MRAs, spironolactone and eplerenone, are both effective in reducing mortality and hospitalization in the treatment of heart failure [22, 23]; however, their role in reducing the rate of progression of kidney disease to ESKD is unknown.”
BackgroundSelf-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“However, despite the use of ACEis or ARBs and the concomitant use of SGLT2is, there remains an unmet need to reduce both the residual risk of progression to ESKD and CV morbidity and mortality [11, 14].”
BackgroundSelf-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111 · cited 1×
“The available steroidal MRAs, spironolactone and eplerenone, are both effective in reducing mortality and hospitalization in the treatment of heart failure [22, 23]; however, their role in reducing the rate of progression of kidney disease to ESKD is unknown.”
BackgroundSelf-citationDiabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898 · cited 1×
“However, despite the use of ACEis or ARBs and the concomitant use of SGLT2is, there remains an unmet need to reduce both the residual risk of progression to ESKD and CV morbidity and mortality [11, 14].”
BackgroundAndrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213 · cited 2×
“Albuminuria is an independent risk marker for CV and allcause mortality, even at levels within the upper normal range [8, 9].”
BackgroundPlasma aldosterone regulation in anephric man
Walker, W. G., & Cooke, C. R. (1973) · Kidney International · doi:10.1038/ki.1973.1 · Cited by 1,841
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Research works printed but not linked: 2
- International Diabetes Federation, 2019, IDF Diabetes Atlas
- Pavkov, 2018, Diabetes in America
Cited by
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citationAgarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
“They investigated the efficacy and safety of finerenone, on top of maximum tolerated renin–angiotensin system inhibition, on kidney and cardiovascular outcomes in patients with mild-to-severe CKD in type 2 diabetes (Supplementary material online, Figure S1).(3) In FIDELIO-DKD, finerenone significantly reduced the risk…”
Self-citationSignaling Pathways Involved in Diabetic Renal Fibrosis
Zhang, Y., Jin, D., Kang, X., Zhou, R., Sun, Y., Lian, F., & Tong, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696542 · Cited by 210
The Bidirectional Link Between Diabetes and Kidney Disease: Mechanisms and Management
Kumar, M., Dev, S., Khalid, M., Siddenthi, S. M., Noman, M., John, C. L., Akubuiro, C., Haider, A., Rani, R., Kashif, M., et al. (2023) · Cureus · doi:10.7759/cureus.45615 · Cited by 159
“Carbohydrates have a notable impact on blood glucose levels, and individuals with diabetes should prioritize consuming complex carbohydrates with a low glycemic index [19].”
BackgroundZhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96
Metadata
- Authors
- Agarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., Joseph, A., & on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators
- Affiliations
- Richard L. Roudebush VA Medical Center (US)
- German Centre for Cardiovascular Research (DE)
- University of Chicago (US)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- University of Copenhagen (DK)
- Hospital Universitario 12 De Octubre (ES)
- Bayer (Germany) (DE)
- Corresponding author
- Agarwal, Rajiv
- ORCID
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-12-06
- Volume
- 37
- Issue
- 6
- Pages
- 1014-1023
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC9130026
- OpenAlex
- W3110972804
- Cited by
- 103
- References
- 44
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 28 · 2023: 23 · 2022: 17 · 2021: 15
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, cc-by-nc-nd)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
- Funders
- Bayer AG
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- finerenone, chronic kidney disease, type 2 diabetes, mineralocorticoid receptor antagonists, diabetic nephropathy, renal failure, cardiovascular outcomes, FIDELIO-DKD, FIGARO-DKD, heart failure, renal fibrosis, quality of life
- MeSH terms
- Mineralocorticoid Receptor Antagonists, Animals, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Renal Dialysis, Humans, Naphthyridines, Quality of Life, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. https://app.cochat.ai/papers/10.1093/ndt/gfaa294
- The paper
- Agarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., Joseph, A., & on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators. (2022). Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaa294
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.